Tarsus Pharmaceuticals, Inc.
TARS
$40.81
$1.995.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 17.96% | 38.01% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 17.96% | 38.01% | |||
| Cost of Revenue | -10.00% | 41.83% | |||
| Gross Profit | 31.62% | 36.22% | |||
| SG&A Expenses | 23.13% | 19.20% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.18% | 23.95% | |||
| Operating Income | -7.61% | 2.94% | |||
| Income Before Tax | -8.68% | 1.31% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -8.68% | 1.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.68% | 1.31% | |||
| EBIT | -7.61% | 2.94% | |||
| EBITDA | -7.63% | 3.57% | |||
| EPS Basic | -6.51% | 1.77% | |||
| Normalized Basic EPS | -27.13% | 13.40% | |||
| EPS Diluted | -6.77% | 1.77% | |||
| Normalized Diluted EPS | -27.13% | 13.40% | |||
| Average Basic Shares Outstanding | 2.03% | 0.47% | |||
| Average Diluted Shares Outstanding | 2.03% | 0.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||